Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Neurology|May 20, 1998
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteersK M JorgaBritish Journal of Clinical Pharmacology|October 6, 1999
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet)K M Jorga, D J NichollEuropean Journal of Clinical Pharmacology|October 1, 1998
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapyK M Jorga, B Fotteler, P Heizmann, et al.European Neurology|August 31, 2000
Effect of tolcapone on the haemodynamic effects and tolerability of desipramineK M Jorga, B Fotteler, M Modi, et al.Journal of Clinical Pharmacology|May 12, 2000
Lack of interaction between tolcapone and tolbutamide in healthy volunteersK M Jorga, B Fotteler, R Gasser, et al.Clinical Pharmacology and Therapeutics|October 23, 1997
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderlyK M Jorga, G Sedek, B Fotteler, et al.European Journal of Neurology|March 4, 1999
The effect of tolcapone on the pharmacokinetics of benserazideK M Jorga, J P Larsen, A Beiske, et al.Clinical Pharmacology and Therapeutics|July 15, 1998
Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolitesK M Jorga, J M Kroodsma, B Fotteler, et al.Clinical Pharmacology and Therapeutics|May 1, 1995
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humansJ Dingemanse, K M Jorga, M Schmitt, et al.Clinical Neuropharmacology|May 10, 2000
Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonismK M Jorga, T L Davis, M C Kurth, et al.Pageof 1